NEW YORK (Reuters) - Genzyme Corp (GENZ.O) shareholder and board member Ralph Whitworth said the “ingredients are there” for a deal with Sanofi-Aventis SA (SASY.PA), but the French drugmaker’s $69-a-share offer is “not even a good starting point” and needs to go “lots higher.”
